The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells
Metrics: PDF 1122 views | HTML 2186 views | ?
Mark P. Labrecque1, Mandeep K. Takhar1, Rebecca Nason1, Stephanie Santacruz1, Kevin J. Tam1,2, Shabnam Massah1, Anne Haegert2, Robert H. Bell2, Manuel Altamirano-Dimas2, Colin C. Collins2, Frank J.S. Lee1, Gratien G. Prefontaine1, Michael E. Cox2, Timothy V. Beischlag1
1The Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada
2Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
Timothy V. Beischlag, e-mail: email@example.com
Keywords: hypoxia, retinoblastoma protein, invasion, neuroendocrine differentiation, prostate cancer
Received: October 23, 2015 Accepted: March 04, 2016 Published: March 23, 2016
Loss of tumor suppressor proteins, such as the retinoblastoma protein (Rb), results in tumor progression and metastasis. Metastasis is facilitated by low oxygen availability within the tumor that is detected by hypoxia inducible factors (HIFs). The HIF1 complex, HIF1α and dimerization partner the aryl hydrocarbon receptor nuclear translocator (ARNT), is the master regulator of the hypoxic response. Previously, we demonstrated that Rb represses the transcriptional response to hypoxia by virtue of its association with HIF1. In this report, we further characterized the role Rb plays in mediating hypoxia-regulated genetic programs by stably ablating Rb expression with retrovirally-introduced short hairpin RNA in LNCaP and 22Rv1 human prostate cancer cells. DNA microarray analysis revealed that loss of Rb in conjunction with hypoxia leads to aberrant expression of hypoxia-regulated genetic programs that increase cell invasion and promote neuroendocrine differentiation. For the first time, we have established a direct link between hypoxic tumor environments, Rb inactivation and progression to late stage metastatic neuroendocrine prostate cancer. Understanding the molecular pathways responsible for progression of benign prostate tumors to metastasized and lethal forms will aid in the development of more effective prostate cancer therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.